Nav: Home

In cancer immunotherapy, one PD-L1 test to rule them all?

December 01, 2016

Clinical trials have proven the power of immunotherapies targeting PD-L1 or PD-1 in a range of cancers. However, these same trials show that only some patients benefit - tumors must depend on PD-L1 to be affected when medicines block its action. In response, the companies Merck, AstraZeneca, Genentech/Roche, and Bristol-Myers Squibb together with the diagnostic companies Ventana and Dako have developed four tests to predict which tumors do and do not express on PD-L1 and thus which tumors will respond to the therapies. An ambitious collaboration between these companies and research organizations including the International Association for the Study of Lung Cancer, the American Association for Cancer Research, and academic medical centers including the University of Colorado Cancer Center, results in a study published online today in the Journal of Thoracic Oncology comparing these four tests.

The study, called the "Blueprint PD-L1 IHC Assay Comparison Project," used all four tests to evaluate 38 samples of human non-small cell lung cancer. In all four tests, half of the tumors were positive for PD-L1 and 5 of the tumors were negative. However, in 14 of 38 cases (37 percent), some tests considered the sample positive while others considered it negative. The disagreement implies that the choice of test used to determine a tumor's PD-L1 dependence may influence whether or not a patient is offered anti-PD-L1 therapy.

"Immunotherapy is evolving very fast and with very encouraging results in lung cancer as well as other cancers. However, a main issue is how to select patients for these therapies. Each company is pursuing their own predictive PD-L1 assay in order to select patients. However, the PD-L1 assays are all different in terms of antibody used and cut-off values for positive/negative results," says Fred R. Hirsch MD, PhD, investigator at the University of Colorado Cancer Center and CEO of the International Association for the Study of Lung Cancer.

With support from the U.S. Food and Drug Administration, Hirsch brought together the four pharmaceutical companies and the two diagnostic companies with leading PD-L1 assays to explore their agreements and discrepancies.

Importantly, each test is paired with a drug - the drug pembrolizumab, developed by Merck, is prescribed based on results from the assay called 22C3; the drug nivolumab, developed by Bristol-Myers Squibb, is paired with an assay called 28-8; likewise, atezolizumab by Genentech/Roche and durvalumab by AstraZeneca are both paired with assays specific to the compound. In fact, this mimics the way in which targeted therapies generally earn FDA approval - a drug and a test determining which patients will benefit from the drug tend to be approved in tandem.

However, all four of these drugs target a tumor's ability to hide from the immune system by the expression of PD-L1, which interacts with the protein PD-1 expressed on immune cells in a way that deactivates these immune cells against tumor tissue. However, by blocking the interaction between PD-L1 and PD-1 the immune cells (T-lymphocytes) remain activated against tumor tissue. In theory, any of these four tests should be able to predict the benefit of any of these four drugs. Critically, each measures how much PD-L1 protein is expressed on the membranes of tumor cells and, based on clinical trial data, how much PD-L1 must be expressed in order for the drug to show benefit.

"Rather than black and white, this can be a grey area. It is not that some tumors express PD-L1 and others do not, but rather that tumors express PD-L1 across a gradient and at some cutoff point in that gradient, the expression becomes clinically relevant," Hirsch says.

Results show that three of the four tests tend to cluster together in their results. Also, differences in these tests meant that there was no absolute cutoff in the amount of PD-L1 that made a sample positive or negative - the different tests must be evaluated by their own scales.

Now with results in hand for the first phase of this study, the comparison will continue into a second phase by comparing these test results to patient outcomes. Basically, the goal is to determine which test allowed doctors to prescribe PD-L1 inhibitors to the patients who benefit, while avoiding the use of these drugs with patients who went on to see little or no benefit.

"This is a unique study based on a unique partnership meant to solve a very important clinical problem," Hirsch says. It might not be long before the field of anti-PD-L1 cancer immunotherapies receives a peer-reviewed recommendation for the one test that will rule them all.
-end-


University of Colorado Anschutz Medical Campus

Related Lung Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.
Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.
Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.
Better equipped in the fight against lung cancer
Lung cancer is the third most common type of cancer in Germany and the disease affects both men and women.
New liquid biopsy-based cancer model reveals data on deadly lung cancer
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes.
Cancer drug leads to 'drastic decrease' in HIV infection in lung cancer patient
Doctors in France have found the first evidence that a cancer drug may be able to eradicate HIV-infected cells in humans.
Air pollution is associated with cancer mortality beyond lung cancer
A large scale epidemiological study associates some air pollutants with kidney, bladder and colorectal cancer death.
Free lung-cancer screening in the Augusta area finds more than double the cancer rate of previous screenings
The first year of free lung cancer screening in the Augusta, Ga., area found more than double the rate seen in a previous large, national study as well as a Massachusetts-based screening for this No.
More Lung Cancer News and Lung Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.